These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 11571643)

  • 21. Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol.
    Kunz C; Borghouts C; Buerger C; Groner B
    Mol Cancer Res; 2006 Dec; 4(12):983-98. PubMed ID: 17189388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.
    Sloots A; Mastini C; Rohrbach F; Weth R; Curcio C; Burkhardt U; Jäger E; Forni G; Cavallo F; Wels WS
    Clin Cancer Res; 2008 Nov; 14(21):6933-43. PubMed ID: 18980988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetically targeted T cells eradicate established breast cancer in syngeneic mice.
    Wang H; Wei H; Zhang R; Hou S; Li B; Qian W; Zhang D; Kou G; Dai J; Guo Y
    Clin Cancer Res; 2009 Feb; 15(3):943-50. PubMed ID: 19188165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
    Witters LM; Witkoski A; Planas-Silva MD; Berger M; Viallet J; Lipton A
    Oncol Rep; 2007 Feb; 17(2):465-9. PubMed ID: 17203189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epithelial component of host-tumor interactions in the orthotopic site preference of a mouse mammary tumor.
    Miller FR; McInerney D
    Cancer Res; 1988 Jul; 48(13):3698-701. PubMed ID: 3378213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.
    Salatino M; Schillaci R; Proietti CJ; Carnevale R; Frahm I; Molinolo AA; Iribarren A; Charreau EH; Elizalde PV
    Oncogene; 2004 Jul; 23(30):5161-74. PubMed ID: 15122317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p130Cas is an essential transducer element in ErbB2 transformation.
    Cabodi S; Tinnirello A; Bisaro B; Tornillo G; del Pilar Camacho-Leal M; Forni G; Cojoca R; Iezzi M; Amici A; Montani M; Eva A; Di Stefano P; Muthuswamy SK; Tarone G; Turco E; Defilippi P
    FASEB J; 2010 Oct; 24(10):3796-808. PubMed ID: 20505116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells.
    Youngren JF; Gable K; Penaranda C; Maddux BA; Zavodovskaya M; Lobo M; Campbell M; Kerner J; Goldfine ID
    Breast Cancer Res Treat; 2005 Nov; 94(1):37-46. PubMed ID: 16142439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.
    Rusnak DW; Affleck K; Cockerill SG; Stubberfield C; Harris R; Page M; Smith KJ; Guntrip SB; Carter MC; Shaw RJ; Jowett A; Stables J; Topley P; Wood ER; Brignola PS; Kadwell SH; Reep BR; Mullin RJ; Alligood KJ; Keith BR; Crosby RM; Murray DM; Knight WB; Gilmer TM; Lackey K
    Cancer Res; 2001 Oct; 61(19):7196-203. PubMed ID: 11585755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atorvastatin modulates anti-proliferative and pro-proliferative signals in Her2/neu-positive mammary cancer.
    Riganti C; Pinto H; Bolli E; Belisario DC; Calogero RA; Bosia A; Cavallo F
    Biochem Pharmacol; 2011 Nov; 82(9):1079-89. PubMed ID: 21803026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Growth factor dependency and gene expression in preneoplastic mouse mammary epithelial cells.
    Medina D; Kittrell FS; Oborn CJ; Schwartz M
    Cancer Res; 1993 Feb; 53(3):668-74. PubMed ID: 8425201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.
    Safavy A; Bonner JA; Waksal HW; Buchsbaum DJ; Gillespie GY; Khazaeli MB; Arani R; Chen DT; Carpenter M; Raisch KP
    Bioconjug Chem; 2003; 14(2):302-10. PubMed ID: 12643740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors.
    Liu JC; Deng T; Lehal RS; Kim J; Zacksenhaus E
    Cancer Res; 2007 Sep; 67(18):8671-81. PubMed ID: 17875707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis.
    Julien SG; Dubé N; Read M; Penney J; Paquet M; Han Y; Kennedy BP; Muller WJ; Tremblay ML
    Nat Genet; 2007 Mar; 39(3):338-46. PubMed ID: 17259984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family.
    Bishop PC; Myers T; Robey R; Fry DW; Liu ET; Blagosklonny MV; Bates SE
    Oncogene; 2002 Jan; 21(1):119-27. PubMed ID: 11791182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tranilast inhibits the growth and metastasis of mammary carcinoma.
    Chakrabarti R; Subramaniam V; Abdalla S; Jothy S; Prud'homme GJ
    Anticancer Drugs; 2009 Jun; 20(5):334-45. PubMed ID: 19322072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Curcumin induces apoptosis in breast cancer cell lines and delays the growth of mammary tumors in neu transgenic mice.
    Masuelli L; Benvenuto M; Fantini M; Marzocchella L; Sacchetti P; Di Stefano E; Tresoldi I; Izzi V; Bernardini R; Palumbo C; Mattei M; Lista F; Galvano F; Modesti A; Bei R
    J Biol Regul Homeost Agents; 2013; 27(1):105-19. PubMed ID: 23489691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of epithelial abnormalities that resemble human breast lesions by the expression of the neu/erbB-2 oncogene in reconstituted mouse mammary gland.
    Bradbury JM; Arno J; Edwards PA
    Oncogene; 1993 Jun; 8(6):1551-8. PubMed ID: 8099220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice.
    Boggio K; Di Carlo E; Rovero S; Cavallo F; Quaglino E; Lollini PL; Nanni P; Nicoletti G; Wolf S; Musiani P; Forni G
    Cancer Res; 2000 Jan; 60(2):359-64. PubMed ID: 10667588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strain-dependent susceptibility to radiation-induced mammary cancer is a result of differences in epithelial cell sensitivity to transformation.
    Ullrich RL; Bowles ND; Satterfield LC; Davis CM
    Radiat Res; 1996 Sep; 146(3):353-5. PubMed ID: 8752316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.